{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T11:02:21Z","timestamp":1792839741990,"version":"4.5.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2023,10,13]],"date-time":"2023-10-13T00:00:00Z","timestamp":1697155200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,10,13]],"date-time":"2023-10-13T00:00:00Z","timestamp":1697155200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP23fk0210113"],"award-info":[{"award-number":["JP23fk0210113"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004206","name":"Osaka University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004206","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Gastroenterol"],"published-print":{"date-parts":[[2023,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>The prognosis of cirrhosis is clearly stratified by liver function. Although direct-acting antiviral (DAA) has recently been used to eliminate hepatitis C virus (HCV), it is not clear whether liver function stratifies the prognosis of decompensated cirrhotic patients treated with DAA.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>A total of 206 HCV-associated decompensated cirrhotic patients who started DAA from February 2019 to December 2021 at 31 Japanese hospitals were prospectively registered.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The median age was 68, and the proportions of patients with Child\u2013Pugh class A (CP-A), CP-B and CP-C were 10% (20\/206), 76% (156\/206) and 15% (30\/206), respectively. Twenty-six patients died, and two patients underwent liver transplantation (LT); the 2- and 3-year LT-free survival rates were 90.0% and 83.2%, respectively. We examined factors associated with LT-free survival using 2 models including either CP class (Model 1) or MELD score (Model 2). In multivariate Cox proportional hazard analysis, CP class at 12\u00a0weeks after the end of treatment (EOT) in Model 1 and MELD score at 12\u00a0weeks after the EOT in Model 2 were significant factors, while baseline CP class or MELD score was not. Two-year LT-free survival rates were 100%, 91.6% and 60.4% for patients with CP-A, CP-B and CP-C at 12\u00a0weeks after the EOT and 95.2% and 69.6% for patients with MELD\u2009&lt;\u200915 and MELD\u2009\u2265\u200915 at 12\u00a0weeks after the EOT, respectively.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>The prognosis of decompensated cirrhotic patients receiving DAA was stratified by liver function at 12\u00a0weeks after the EOT, not by baseline liver function.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00535-023-02039-x","type":"journal-article","created":{"date-parts":[[2023,10,13]],"date-time":"2023-10-13T05:01:56Z","timestamp":1697173316000},"page":"1211-1221","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Posttreatment liver function, but not baseline liver function stratifies patient survival after direct-acting antiviral treatment in decompensated cirrhosis with hepatitis C virus"],"prefix":"10.1007","volume":"58","author":[{"given":"Yuki","family":"Tahata","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hayato","family":"Hikita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Mochida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuyuki","family":"Enomoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akio","family":"Ido","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidekatsu","family":"Kuroda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daiki","family":"Miki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayuki","family":"Kurosaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoichi","family":"Hiasa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryotaro","family":"Sakamori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norifumi","family":"Kawada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taro","family":"Yamashita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Goki","family":"Suda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Yatsuhashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hitoshi","family":"Yoshiji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoya","family":"Kato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taro","family":"Takami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiko","family":"Nakao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kentaro","family":"Matsuura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhiro","family":"Asahina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshito","family":"Itoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryosuke","family":"Tateishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasunari","family":"Nakamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eiji","family":"Kakazu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuji","family":"Terai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahito","family":"Shimizu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiyuki","family":"Ueno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norio","family":"Akuta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masanori","family":"Miyazaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasutoshi","family":"Nozaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayuki","family":"Kabayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Sobue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiro","family":"Moriuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomokatsu","family":"Miyaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Kodama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomohide","family":"Tatsumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomomi","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5036-3457","authenticated-orcid":false,"given":"Tetsuo","family":"Takehara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,10,13]]},"reference":[{"key":"2039_CR1","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.jhep.2005.10.013","volume":"44","author":"G D'Amico","year":"2006","unstructured":"D\u2019Amico G, Garcia-Tsao G, Pagliaro L. Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. J Hepatol. 2006;44:217\u201331.","journal-title":"J Hepatol"},{"key":"2039_CR2","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1111\/hepr.13711","volume":"51","author":"H Yamana","year":"2021","unstructured":"Yamana H, Imai S, Yamasaki K, et al. Prognosis of patients with liver cirrhosis: A multi-center retrospective observational study. Hepatol Res. 2021;51:1196\u2013206.","journal-title":"Hepatol Res"},{"key":"2039_CR3","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1016\/j.jhep.2004.01.005","volume":"40","author":"R Planas","year":"2004","unstructured":"Planas R, Balleste B, Alvarez MA, et al. Natural history of decompensated hepatitis C virus-related cirrhosis. A study of 200 patients. J Hepatol. 2004;40:823\u201330.","journal-title":"J Hepatol"},{"key":"2039_CR4","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1111\/hepr.13623","volume":"51","author":"K Maesaka","year":"2021","unstructured":"Maesaka K, Sakamori R, Yamada R, et al. Clinical course of hepatitis C virus-positive patients with decompensated liver cirrhosis in the era of direct-acting antiviral treatment. Hepatol Res. 2021;51:517\u201327.","journal-title":"Hepatol Res"},{"key":"2039_CR5","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1186\/s12876-021-01770-0","volume":"21","author":"S Fujiyama","year":"2021","unstructured":"Fujiyama S, Akuta N, Sezaki H, et al. Mortality rates and risk factors in 1412 Japanese patients with decompensated hepatitis C virus-related cirrhosis: a retrospective long-term cohort study. BMC Gastroenterol. 2021;21:189.","journal-title":"BMC Gastroenterol"},{"key":"2039_CR6","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/s00535-020-01733-4","volume":"56","author":"Y Tahata","year":"2021","unstructured":"Tahata Y, Hikita H, Mochida S, et al. Sofosbuvir plus velpatasvir treatment for hepatitis C virus in patients with decompensated cirrhosis: a Japanese real-world multicenter study. J Gastroenterol. 2021;56:67\u201377.","journal-title":"J Gastroenterol"},{"key":"2039_CR7","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1111\/hepr.13576","volume":"51","author":"Y Takaoka","year":"2021","unstructured":"Takaoka Y, Miura K, Morimoto N, et al. Real-world efficacy and safety of 12-week sofosbuvir\/velpatasvir treatment for patients with decompensated liver cirrhosis caused by hepatitis C virus infection. Hepatol Res. 2021;51:51\u201361.","journal-title":"Hepatol Res"},{"key":"2039_CR8","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1111\/hepr.13739","volume":"52","author":"M Atsukawa","year":"2022","unstructured":"Atsukawa M, Tsubota A, Kondo C, et al. Time-course changes in liver functional reserve after successful sofosbuvir\/velpatasvir treatment in patients with decompensated cirrhosis. Hepatol Res. 2022;52:235\u201346.","journal-title":"Hepatol Res"},{"key":"2039_CR9","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1007\/s12072-018-9914-6","volume":"13","author":"I Gentile","year":"2019","unstructured":"Gentile I, Scotto R, Coppola C, et al. Treatment with direct-acting antivirals improves the clinical outcome in patients with HCV-related decompensated cirrhosis: results from an Italian real-life cohort (Liver Network Activity-LINA cohort). Hepatol Int. 2019;13:66\u201374.","journal-title":"Hepatol Int"},{"issue":"4","key":"2039_CR10","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1007\/s00535-023-01963-2","volume":"58","author":"K Kotani","year":"2023","unstructured":"Kotani K, Enomoto M, Uchida-Kobayashi S, et al. Short-term hepatocyte function and portal hypertension outcomes of sofosbuvir\/velpatasvir for decompensated hepatitis C-related cirrhosis. J Gastroenterol. 2023;58(4):394.","journal-title":"J Gastroenterol"},{"key":"2039_CR11","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1111\/hepr.13837","volume":"53","author":"T Sano","year":"2023","unstructured":"Sano T, Amano K, Ide T, et al. A combination of hepatic encephalopathy and body mass index was associated with the point of no return for improving liver functional reserve after sofosbuvir\/velpatasvir treatment in patients with hepatitis C virus-related decompensated cirrhosis. Hepatol Res. 2023;53:26\u201334.","journal-title":"Hepatol Res"},{"key":"2039_CR12","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1007\/s00535-021-01845-5","volume":"57","author":"Y Tahata","year":"2022","unstructured":"Tahata Y, Hikita H, Mochida S, et al. Liver-related events after direct-acting antiviral therapy in patients with hepatitis C virus-associated cirrhosis. J Gastroenterol. 2022;57:120\u201332.","journal-title":"J Gastroenterol"},{"key":"2039_CR13","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1111\/hepr.13503","volume":"50","author":"Drafting Committee for Hepatitis Management Guidelines tJSoH","year":"2020","unstructured":"Drafting Committee for Hepatitis Management Guidelines tJSoH. Japan Society of Hepatology guidelines for the management of hepatitis C virus infection: 2019 update. Hepatol Res. 2020;50:791\u2013816.","journal-title":"Hepatol Res"},{"key":"2039_CR14","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1007\/s00535-021-01788-x","volume":"56","author":"H Yoshiji","year":"2021","unstructured":"Yoshiji H, Nagoshi S, Akahane T, et al. Evidence-based clinical practice guidelines for Liver Cirrhosis 2020. J Gastroenterol. 2021;56:593\u2013619.","journal-title":"J Gastroenterol"},{"key":"2039_CR15","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1111\/hepr.13678","volume":"51","author":"H Yoshiji","year":"2021","unstructured":"Yoshiji H, Nagoshi S, Akahane T, et al. Evidence-based clinical practice guidelines for liver cirrhosis 2020. Hepatol Res. 2021;51:725\u201349.","journal-title":"Hepatol Res"},{"key":"2039_CR16","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","volume":"42","author":"PA Harris","year":"2009","unstructured":"Harris PA, Taylor R, Thielke R, et al. Research electronic data capture (REDCap)\u2013a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009;42:377\u201381.","journal-title":"J Biomed Inform"},{"key":"2039_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbi.2019.103208","volume":"95","author":"PA Harris","year":"2019","unstructured":"Harris PA, Taylor R, Minor BL, et al. The REDCap consortium: Building an international community of software platform partners. J Biomed Inform. 2019;95: 103208.","journal-title":"J Biomed Inform"},{"key":"2039_CR18","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1053\/he.2000.5852","volume":"31","author":"M Malinchoc","year":"2000","unstructured":"Malinchoc M, Kamath PS, Gordon FD, et al. A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts. Hepatology. 2000;31:864\u201371.","journal-title":"Hepatology"},{"key":"2039_CR19","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1053\/jhep.2001.22172","volume":"33","author":"PS Kamath","year":"2001","unstructured":"Kamath PS, Wiesner RH, Malinchoc M, et al. A model to predict survival in patients with end-stage liver disease. Hepatology. 2001;33:464\u201370.","journal-title":"Hepatology"},{"key":"2039_CR20","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1053\/gast.2003.50016","volume":"124","author":"R Wiesner","year":"2003","unstructured":"Wiesner R, Edwards E, Freeman R, et al. Model for end-stage liver disease (MELD) and allocation of donor livers. Gastroenterology. 2003;124:91\u20136.","journal-title":"Gastroenterology"},{"issue":"2","key":"2039_CR21","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1111\/hepr.13848","volume":"53","author":"K Kumagai","year":"2022","unstructured":"Kumagai K, Mawatari S, Moriuchi A, et al. Early-phase prothrombin time-international normalized ratio in acute liver injury indicates the timing of therapeutic intervention and predicts prognostic improvement. Hepatol Res. 2022;53(2):160.","journal-title":"Hepatol Res"},{"key":"2039_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.bjid.2022.102697","volume":"26","author":"GH Pereira","year":"2022","unstructured":"Pereira GH, Peixoto HR, Giusti ML, et al. Long-term survival and clinical outcomes following direct-acting antiviral (DAA) treatment in HCV decompensated cirrhosis in Brazil: a real-world study. Braz J Infect Dis. 2022;26: 102697.","journal-title":"Braz J Infect Dis"},{"issue":"2111\u20132121","key":"2039_CR23","volume":"154","author":"O El-Sherif","year":"2018","unstructured":"El-Sherif O, Jiang ZG, Tapper EB, et al. Baseline factors associated with improvements in decompensated cirrhosis after direct-acting antiviral therapy for hepatitis C virus infection. Gastroenterology. 2018;154(2111\u20132121): e2118.","journal-title":"Gastroenterology"},{"key":"2039_CR24","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1002\/hep.27210","volume":"60","author":"H Vilstrup","year":"2014","unstructured":"Vilstrup H, Amodio P, Bajaj J, et al. Hepatic encephalopathy in chronic liver disease: 2014 practice guideline by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver. Hepatology. 2014;60:715\u201335.","journal-title":"Hepatology"},{"key":"2039_CR25","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1016\/j.jhep.2020.11.021","volume":"74","author":"LAP Krassenburg","year":"2021","unstructured":"Krassenburg LAP, Maan R, Ramji A, et al. Clinical outcomes following DAA therapy in patients with HCV-related cirrhosis depend on disease severity. J Hepatol. 2021;74:1053\u201363.","journal-title":"J Hepatol"},{"key":"2039_CR26","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1186\/s12879-022-07076-0","volume":"22","author":"GP Pageaux","year":"2022","unstructured":"Pageaux GP, Nzinga CL, Ganne N, et al. Clinical outcomes after treatment with direct antiviral agents: beyond the virological response in patients with previous HCV-related decompensated cirrhosis. BMC Infect Dis. 2022;22:94.","journal-title":"BMC Infect Dis"},{"key":"2039_CR27","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1111\/hepr.13868","volume":"53","author":"Y Tahata","year":"2023","unstructured":"Tahata Y, Sakamori R, Maesaka K, et al. Effect of sofosbuvir and velpatasvir therapy on clinical outcome in hepatitis C virus patients with decompensated cirrhosis. Hepatol Res. 2023;53:301\u201311.","journal-title":"Hepatol Res"},{"key":"2039_CR28","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/s00535-018-1503-x","volume":"54","author":"T Takehara","year":"2019","unstructured":"Takehara T, Sakamoto N, Nishiguchi S, et al. Efficacy and safety of sofosbuvir-velpatasvir with or without ribavirin in HCV-infected Japanese patients with decompensated cirrhosis: an open-label phase 3 trial. J Gastroenterol. 2019;54:87\u201395.","journal-title":"J Gastroenterol"}],"container-title":["Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00535-023-02039-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00535-023-02039-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00535-023-02039-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,19]],"date-time":"2023-11-19T15:04:05Z","timestamp":1700406245000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00535-023-02039-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,13]]},"references-count":28,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["2039"],"URL":"https:\/\/doi.org\/10.1007\/s00535-023-02039-x","relation":{},"ISSN":["0944-1174","1435-5922"],"issn-type":[{"value":"0944-1174","type":"print"},{"value":"1435-5922","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,13]]},"assertion":[{"value":"18 July 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 August 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 October 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Satoshi Mochida received lecture fees from Gilead Sciences, Inc., AbbVie GK., ASKA Pharmaceutical Co., Ltd., Toray Industries Inc., Otuska Pharmaceutical Co., Ltd. and Eisai Co., Ltd. Masayuki Kurosaki received lecture fees from Gilead, AbbVie, Eisai, Chugai, AstraZeneca, Lilly and Takeda. Norifumi Kawada received research grants from AstraZeneca plc., Bristol Myers Squibb., Glaxosmithkline plc., MSD co., ltd., Gilead Sciences. Inc. and NovoNordisk pharma Ltd., scholarship grants from AbbVie GK, Eisai Co., Ltd. and Otsuka Pharmaceutical Co. and received lecture fees from AbbVie GK, Gilead Sciences, Inc. and MSD Co., Ltd. Goki Suda received research grants from Gilead Sciences Inc. Hitoshi Yoshiji received lecture fees from Gilead Sci. Naoya Kato received research grants from AbbVie G.K., scholarship grants from Gilead Sciences Inc., and lecture fees from Gilead Sciences, Inc. and AbbVie G.K. Taro Takami received lecture fees from Gilead Sciences, Inc. Yasuhiro Asahina belongs to a donation-funded department funded by Fujirebio Inc. and Abbott Japan LLC. Yoshito Itoh received research grants from Merck Sharp and Dohme., scholarship grants from AbbVie Inc. and Takeda Pharm. Co.Ltd. and lecture fees from AbbVie Inc and Gilead Sciences Inc. Shuji Terai received lecture fees from Otsuka, AbbVie, Asuka, Daiichisankyo, Chiomu Takedansen and Gilead. Yoshiyuki Ueno received lecture fees from AbbVie Inc. Norio Akuta received lecture fees from AbbVie Inc. Tetsuo Takehara received research grants and lecture fees from AbbVie GK. and Gilead Sciences, Inc. All other authors declare that they have no conflicts of interest to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"University Hospital Medical Information Network (UMIN: 36150).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Trial registration number"}}]}}